- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Malvern Today
By the People, for the People
Aclaris Therapeutics Misses Q4 Earnings Expectations
Biotech company reports $0.16 loss per share, falling short of $0.15 consensus estimate
Published on Feb. 26, 2026
Got story updates? Submit your updates here. ›
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on dermatologic diseases, announced its fourth quarter earnings results on Thursday. The company reported a loss of $0.16 per share, missing the consensus estimate of a $0.15 loss per share. Aclaris also reported revenue of $1.30 million for the quarter, falling short of the $2.07 million analysts had expected.
Why it matters
Aclaris Therapeutics is a closely watched biotech company with a pipeline of promising dermatology drug candidates. The company's earnings miss and lower-than-expected revenue could raise concerns among investors about the progress of Aclaris' clinical programs and its ability to commercialize future products.
The details
In its earnings report, Aclaris Therapeutics cited a negative net margin of 900.01% and a negative return on equity of 39.73%. The company attributed the miss to lower-than-expected revenue, which it said was due to timing of certain milestones and collaborations.
- Aclaris Therapeutics announced its Q4 2026 earnings results on Thursday, February 26, 2026.
The players
Aclaris Therapeutics
A clinical-stage biopharmaceutical company focused on developing novel therapies for dermatologic diseases and related rare disorders.
What’s next
Aclaris Therapeutics is expected to provide updates on the progress of its key drug candidates, including bosakitug, ATI-052, and ATI-2138, throughout 2026.
The takeaway
Aclaris Therapeutics' Q4 earnings miss highlights the challenges facing clinical-stage biotech companies as they work to advance their pipelines and eventually commercialize new products. Investors will be closely watching the company's upcoming milestones and data readouts to gauge the potential of its dermatology-focused drug candidates.
